<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article329</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ASCEND_(IPF)" style="display:block; margin-bottom:10px;">ASCEND (IPF) Original</a></li>
<h2><strong>ASCEND (IPF)</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis".The New England Journal of Medicine. 2014. Published online before print.<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcomes<br/>
8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does pirfenidone reduce disease progression in patients with idiopathic pulmonary fibrosis compared to placebo?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Pirfenidone, compared to placebo, reduced disease progression as measured by FVC change, 6-minute walk distance, and progression-free survival in patients with idiopathic pulmonary fibrosis, and had an acceptable side-effect profile with fewer deaths observed.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease. Previous phase 3 trials demonstrated mixed results regarding the efficacy of pirfenidone in reducing disease progression. The phase 3 ASCEND trial aimed to confirm pirfenidone's beneficial effect on disease progression in IPF patients.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Guideline recommendations for the use of pirfenidone in IPF were not addressed as part of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Phase 3, randomized, double-blind, placebo-controlled trial<br/>
- N=555 patients with idiopathic pulmonary fibrosis<br/>
- Randomized to receive oral pirfenidone (2403 mg per day) or placebo for 52 weeks<br/>
- Primary endpoint: change in FVC or death at week 52<br/>
- Secondary endpoints included the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from IPF<br/>
- Conducted at 127 sites in 9 countries<br/>
- Funding: InterMune<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Adults aged 40-80 years with centrally confirmed diagnosis of IPF<br/>
- Inclusion Criteria: Diagnosed with IPF, FVC 50-90% predicted, FEV1:FVC ratio ≥0.80, 6-minute walk distance ≥150m<br/>
- Exclusion Criteria: Symptomatic ventricular arrhythmias, NSVT ≥15 PVCs per hour at rate ≥120 bpm, use of investigational therapy, etc. <br/>
- Baseline Characteristics: Majority male and white, average age 65 or older, mean baseline FVC 67.8±11.2% predicted in pirfenidone group and 68.6±10.9% predicted in placebo group<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Pirfenidone (2403 mg per day) administered with food in three divided doses, with a gradual dose increase over 2 weeks<br/>
- Placebo administered in a similar regimen<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcomes<br/>
- Significant relative reduction of 47.9% in patients with ≥10 percentage points decline in predicted FVC or death with pirfenidone<br/>
- Relative increase of 132.5% in patients with no decline in FVC with pirfenidone compared to placebo (P&lt;0.001)<br/>
Secondary Outcomes<br/>
- Reduce 6-minute walk distance decline (P=0.04)<br/>
- Improved progression-free survival (P&lt;0.001)<br/>
- No significant difference in dyspnea scores or death rates from any cause or from IPF<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The generalizability to patients with advanced disease and those with significant airflow limitation (FEV1:FVC &lt;0.80) is uncertain<br/>
- Central confirmation of diagnosis may not represent the general IPF population<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- The study was funded by InterMune.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- The full text of the article is available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
